Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) FCF Margin (2020 - 2025)

Neuroone Medical Technologies' FCF Margin history spans 12 years, with the latest figure at 109.13% for Q4 2025.

  • For Q4 2025, FCF Margin fell 11473.0% year-over-year to 109.13%; the TTM value through Dec 2025 reached 71.28%, up 5225.0%, while the annual FY2025 figure was 32.09%, 29030.0% up from the prior year.
  • FCF Margin reached 109.13% in Q4 2025 per NMTC's latest filing, down from 56.05% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1383.43% in Q3 2022 to a low of 13047.53% in Q1 2021.
  • Average FCF Margin over 5 years is 2706.36%, with a median of 444.0% recorded in 2023.
  • Peak YoY movement for FCF Margin: tumbled -545663bps in 2021, then surged 826156bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 8120.86% in 2021, then soared by 62bps to 3057.95% in 2022, then soared by 87bps to 393.45% in 2023, then soared by 101bps to 5.61% in 2024, then plummeted by -2046bps to 109.13% in 2025.
  • Per Business Quant, the three most recent readings for NMTC's FCF Margin are 109.13% (Q4 2025), 56.05% (Q3 2025), and 86.29% (Q2 2025).